green cross cell corp fkq company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile green cross cell corp fkq related topics stocksstock screenertechnologyelectronic equipments  parts overview news key developments people charts financials analysts research pulse fkq on kosdaq  korea secs dealers association quotation krw  dec  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description green cross cell corporation is a koreabased company mainly engaged in the manufacture of electronic components through its subsidiaries the company operates in two business divisions it segment and biotechnology segment its it segment exports computer peripherals to overseas markets such as liquid crystal display lcd monitors its biotechnology segment provides immune cell therapy immune cell cryopreservation service and cord blood cryopreservation service through its subsidiaries it also involves in the manufacture of electronic components including industrial tapes and others on april   it changed its name to green cross cell corporation from innocell corporation » full overview of fkq company address green cross cell corp f  beotkkotro geumcheonseoul      p f  company web links home page officers  directors name compensation deuk ju lee  jong seong choi  hyo won kim  jong seong ahn  yu gyeong hwang  » more officers  directors green cross cell corp news » more fkq news related topics stocksstock screenertechnologyelectronic equipments  parts green cross cell corp kq quote reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states green cross cell corp kq related topics stocksstock screenermarket datatechnologyelectronic equipments  parts overview news key developments people charts financials analysts research kq on kosdaq  korea secs dealers association quotation krw  aug  change  chg ₩  prev close ₩ open ₩ days high ₩ days low ₩ volume  avg vol  wk high ₩ wk low ₩ kq about green cross cell corporation is a koreabased company mainly engaged in the manufacture of electronic components through its subsidiaries the company operates in two business divisions it segment and biotechnology segment its it segment exports computer peripherals to overseas markets such as liquid crystal display lcd more buysell no analyst recommendations are available for kq » analyst consensus overall beta  market capmil ₩ shares outstandingmil  dividend  yield   financials   kq industry sector pe ttm    eps ttm    roi    roe    latest news about kq » more kq news earnings vs estimates related topics stocksstock screenermarket datatechnologyelectronic equipments  parts green cross  about us  relative  pharmaceutical about us business r  d products investors newsroom overview mission  vision core value responsibility plant history affiliated companies locations business development marketingsales procurement  supply introduction research institutes pipeline rampd network green cross green cross holdings news worldwide contact us careers korea affiliated companies about usaffiliated companiespharmaceutical pharmaceutical healthcare overseas foundation etc green cross cell after successfully developing the cancer immunotherapy immuncelllc and obtaining approval in  for it as a treatment for liver cancer green cross cell continues to specialize in innovative cell therapy successful threephase clinical trials on immuncelllc’s efficacy in treating liver cancer and brain cancer glioblastoma or gbm have been completed green cross cell today is developing cart a nextgeneration cell therapy and is working with toolgen to find and develop nextgeneration cancer immunotherapies based on t cells which would have powerful anticarcinogenic effects homepagewwwgreencrosscellcomengmainasp date of foundation january  office addresth floor  beotkkotro geumcheongu seoul   korea tel fax green cross medical science corporation starting out with the development of a diagnostic test for blood types in  green cross ms became the first company in korea to develop a diagnostic test for aids in  the company has also developed a diagnostic test for hemorrhagic fever with renal syndrome in  green cross ms produces over  diagnostic agents for approximately  diseases the company today is focusing on developing molecular diagnostic technology that would enable precise detection of lifethreatening viruses such as hiv and hepatitis homepagehttpwwwgreencrossmscom date of foundationdecember  office address ihyeonro beongil giheunggu yonginsi  gyeonggido korea tel fax green cross wellbeing green cross wellbeing is a newly established company through green cross jbp acquiring green cross hs and green cross wb operation division in order to become a leader of healthcare solution in an era of longevity we not only offer personalized healthcare solution such as individual customized nutrient medication and health supplement food but also research and develop natural medical supplies and health functional food homepagehttpwwwgreencrosswbcom date of foundationseptember  office addres dodam bldg bf  hwangsaeulro bundanggu seongnamsi gyeonggido korea tel  fax  about us overview mission  vision core value responsibility plant history affiliated companies locations  ihyeonro beongil giheunggu yonginsi gyeonggido korea green cross corp tel  fax  copyright ⓒ  green cross corp all rights reserved kosdaq stock quote  green cross cell corp  bloomberg markets error could not add to watchlist x  watchlist green cross cell corp ks kosdaq krw   as of  am edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share krw ttm  market cap b krw  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector information technology  price change  industry technology hardware  equipment  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later there are currently no press releases for this ticker please check back later profile green cross cell corp develops bioproducts such as immunity cell therapy autologous lymphocyte cord blood and tumor cell bank the company provides extreme drug resistance assay edr testing services address  beotkkotrogeumcheonguseoul korea republic of south phone  website wwwgreencrosscellcom executives board members lee deukjoo ceorep director sagong younghee managing director an jongseong managing director kang kiwon managing director jung kyuchul managing director show more green cross labcell corp company profile  bloomberg feedback green cross labcell corp public company company profile sector consumer discretionary industry commercial services subindustry other commercial services green cross labcell corp is a biotechnology company that researches and develops cell therapy products the company is also engaged in cell banking clinical laboratory services clinical trial and biologistics services corporate information address  ihyeonro beongil giheunggu yonginsi gyeonggido  korea republic of south phone  fax  web url wwwgclabcellcom board members ceorep director company park daewoo green cross labcell corp managing director company hwang yukyung green cross labcell corp cfomanaging director company park soonyoung green cross labcell corp board members company from the web key executives park daewoo ceorep director park jongsub senior managing director park soonyoung cfomanaging director hwang yukyung managing director sung pilseok managing director hong sungil managing director sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data green cross cell corp kosdaq quotes  news  google financemy accountsearchmapsyoutubeplaygmaildrivecalendargoogletranslatephotosmoredocsbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinancegreen cross cell corpkosdaqadd to portfoliocompanysummarynewsrelated companieshistorical pricesmarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   green cross cell corp  public kosdaq   watch this stock      aug   close kosdaq data delayed by  mins  disclaimer currency in krw range     week    open  vol  avg  mkt cap b pe  divyield  eps  shares m beta      inst own      news relevance date all news for green cross cell corp » subscribe advertisement key stats and ratios q mar   net profit margin   operating margin   ebitd margin   return on average assets   return on average equity   employees   cdp score   more ratios from thomson reuters » address f  beotkkotro geumcheonguseoul south korea phone fax website links httpwwwgreencrosscellcom settings  technicals  link to this view sources include six advertisement related companies show most recent quarter most recent annual add or remove columns save changes cancel more from factset » description green cross cell corporation is a koreabased company mainly engaged in the manufacture of electronic components through its subsidiaries the company operates in two business divisions it segment and biotechnology segment its it segment exports computer peripherals to overseas markets such as liquid crystal display lcd monitors its biotechnology segment provides immune cell therapy immune cell cryopreservation service and cord blood cryopreservation service through its subsidiaries it also involves in the manufacture of electronic components including industrial tapes and others on april   it changed its name to green cross cell corporation from innocell corporation more from reuters » officers and directors deuk ju lee chief executive officer director age  jong seong choi vice president director age  hyo won kim vice president director age  jong seong ahn director age  yu gyeong hwang director age  chang hui lee director age  chan seop kim nonexecutive independent director age  jong hyeok kim nonexecutive independent director age  full list on reuters » google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service green cross  products about us business r  d products investors newsroom overview mission  vision core value responsibility plant history affiliated companies locations business development marketingsales procurement  supply introduction research institutes pipeline rampd network green cross green cross holdings news worldwide contact us careers korea prescription drugs productsprescription drugs keyword search product type all prescription drugs over the counter drugs enter keyword product name efficacy frequently used keywords novel flu hemophilia influenza albumin a b c d e f g h i j k l m n o p q r s t u v w x y z prescription drugs blood derivatives vaccines cerebrovascular disease treatment hunter syndrome drug recombinant fibrinolytic agent herbal medicine chemotherapy total products neulapeg prefilled syringe inj treatment of neutropenia serotet inj hypertet inj used to provided passive immunization against infection caused by clostridium tetani greenviii inj for the treatment of hemophilia a with supplies of blood coagulation factor viii varicella vaccinegcc inj for prophylaxis of varicella varicellazoster immune globulin passive immunization against chickenpox formulation greengene f inj bleeding symptom control and hemostasis for persons with hemophilia a gc flu prefilled syringe inj prevention of influenza flu ivhepabig inj hepatitis b hepabig inj hepatitis b vaccination  products prescription drugs over the counter drugs  ihyeonro beongil giheunggu yonginsi gyeonggido korea green cross corp tel  fax  copyright ⓒ  green cross corp all rights reserved green cross to build cell therapy manufacturing facility in china green cross to build cell therapy manufacturing facility in china addressing growing demand for new therapies apr    et from green cross yongin south korea april   prnewswire  green cross a south korean biopharmaceutical company today announced plans to build a new cell therapy manufacturing facility at the guian new area in the guizhou province of china the new manufacturing site sets to address the cellular therapeutic industrys demand for clinical studies and commercial supply green cross has a robust and growing portfolio of approved and clinical stage cell therapy projects including t cell nk cell dendritic cell and stem cells cell therapy products are an increasingly significant tool in the treatment of serious diseases our investment reflects the strength of our business and the increasingly important role that cell therapy will play in green cross future said dr bg rhee president of green cross holdings over the last  years green cross has maintained a significant manufacturing facility and sales forces for plasma fractionation business in china and we look forward to building on that legacy through this business expansion the chinese pharmaceutical market has emerged as a major driver of revenue growth for global pharmaceutical companies according to a report from mckinsey  company the report shows that chinas pharmaceutical market has grown at a rapid  compound annual rate over the years in a recent forecast chinas pharmaceutical market is projected to continue to grow at around  annually and likely to become the secondlargest pharmaceutical market by  about green cross green cross provides total healthcare solutions that address the evolving needs of human health headquartered in yongin south korea green cross specialises in the development and manufacturing of plasmaderivatives vaccines and recombinant proteins this release includes forwardlooking statements concerning the companys plans to build a new cell therapy manufacturing facility in china the statements are based on assumptions about many important factors the company does not undertake to update its forwardlooking statements source green cross view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more nov    et preview green cross submits biologics license application to us fda for ivigsn mar    et preview green cross and nanolek announce strategic partnership for biologics commercialisation in russia my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search yahoo yahoo  bing  yam yahoo yahoo    yahoo yahoo yahoo yahoo yahoo  （，） ：      （，） ：                 yahoo digital marketing all rights reserved company overview  green cross biotherapeutics englishfrançais french about gcbt executive message company overview project oasis products plasma derivatives product list green cross products media center customer relations careers contact us company overview green cross biotherapeutics  company overview green cross biotherapeutics inc gcbt established in  gcbt is a montrealbased biopharmaceutical company and a member of the green cross family   canada’s only ivig and albumin manufacturing plant gcbt will be constructing the only intravenous immunoglobulin ivig and albumin manufacturing plant in canada this stateoftheart facility will duly mark the beginning of a new chapter in the history of the canadian biopharmaceutical industry the products that will be manufactured in this facility include intravenous immunoglobulin ivig a key therapeutic solution for the treatment of patients with infectious and immune diseases and albumin used as a bloodvolumizing agent and in the treatment of burns gcbt is planning to expand its business to manufacture and distribute many various bio products in the future government officials and green cross executives pose on june st  at the official ground breaking ceremony in stlaurent quebec a global leader in the healthcare industry green cross corporation provides safe and effective healthcare solutions that address the evolving needs of human health headquartered in yongin south korea the company specializes in the development and manufacturing of plasma derivatives preventive vaccines recombinant proteins and therapeutic antibodies green cross corporation was founded in  with its  subsidiaries it employs over  people worldwide with more than  years of business experience it has become an internationally recognized specialty biopharmaceutical company copyright  green cross corporation  green cross biotherapeutics inc gcbt back to top greencross labcell  alliance for regenerative medicine jump to navigation alliance for regenerative medicine user login log in username or email  password  request new password search form search greencross labcell  ihyeonro beongil giheunggu  yonginsi  south korea see map google maps ticker symbol  website httpwwwgclabcellcom phone  email overseasgreencrosscom media contact gc labcell was established through integrating the cell therapy product business of green cross and the umbilical cord blood storage business of gc lab gc labcell selected the development of incurable disease therapy products using stem cells as well as nk cellbased immunocell therapy products as its strategic business and plans to expand the business into other areas such as stem cell treatment and total healthcare and seek global business based on related technologies and products no related news at this time main menuhome about us members get involved about regenerative medicine events arm in action media center home about usabout arm officers board  executive committee management team contact us membersarm members and profiles become a member member news get involvedbecome a member sign up for our newsletter attend arm events about regenerative medicineindustry overview promise and potential clinical trials  products economics of rm eventsarm eventsadvanced therapies summit arm reception  bio cell  gene exchange cell  gene meeting on the mesa cell  gene therapy investor day eu advanced therapies investor day patient advocacy roundtables state of the industry briefing committee meetings regenerative medicine industry events past events arm in actioncommittees and working groups technology sections european section patient resources  advocacy policy and government relations regulatory reimbursement science and technology regenerative medicine promotion act arm  bioethics arm political action committee regulatory  legislative priorities arm mous media centerarm  annual report arm presentations  publications rm news arm newsletter arm press releases arm in the news media resources members arm members and profiles become a member member news featured biolife solutions executes supply agreement with celyad for cryostor use in natural killer receptor based tcell platform targeting solid tumors and blood cancers july   – biolife – biolife solutions inc announced it has executed a long term supply agreement with nasdaqlisted celyad a newsletter signup regenerative medicine  alzheimers and regenerative medicine  amyotrophic lateral sclerosis als  autoimmune disorders  regenerative medicine  cardiovascular and regenerative medicine  diabetes and regenerative medicine  musculoskeletal and regenerative medicine  ocular disease and regenerative medicine  oncology and regenerative medicine  parkinsons disease  regenerative medicine  rare disease and regenerative medicine home  about us  members  get involved  arm in action  events  about regenerative medicine  media center    alliance for regenerative medicine  site by revunami